HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence

This study is testing a combination of treatments given before and after surgery (perioperative) for liver cancer (hepatocellular carcinoma or HCC) that is operable but at high risk of coming back. The combination includes HAIC (a targeted chemotherapy delivered directly into the liver artery), donafenib (a targeted oral drug), and sintilimab (an immunotherapy drug). **You may be eligible if...** - You are 18–75 years old with confirmed liver cancer (HCC) that has not been treated before - Your cancer can be surgically removed with enough healthy liver remaining - You have at least one large tumor (over 5 cm), multiple tumors, or other high-risk features - You have good liver function (Child-Pugh class A) **You may NOT be eligible if...** - You have already received treatment for your liver cancer - Your liver function is too poor for surgery or the study drugs - Your cancer has spread beyond the liver to other organs or vessels - You have autoimmune conditions incompatible with immunotherapy Talk to your doctor to see if this trial is right for you.